50 results on '"Nicola, Nicolai"'
Search Results
2. Do number of biopsies and PSA doubling time at 3 and 5 years in active surveillance protocols associate with upgrading reclassification?
3. Active surveillance in prostate cancer patients: Predicting the chance of continuing AS after re-biopsy
4. Favourable and reliable PSA doubling time can improve confidence in reducing the number of repeat biopsy during active surveillance
5. Reclassification due to upgrading during active surveillance protocols in low risk prostatic cancer: The role of number of repeat biopsies in the long terms
6. Primary retroperitoneal lymph-node dissection (RPLND) in stage IIA/IIB germ-cell tumours (GCT) of the testis: Is it an effective and safe approach in modern setting?
7. PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)
8. Dacomitinib (Daco) induction therapy for locally-advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): An open label, single-arm, phase 2 study
9. Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase 2 Pazotest trial
10. A validation analysis confirming different predictors of upgrading and upsizing at 1-year repeat biopsy in low-risk prostate cancer patients on active surveillance
11. Effect of number of computed tomography (CT) scans during follow-up (FUP) of patients with clinical stage I (CSI) seminoma: A trial-level meta-analysis
12. Laparoscopic retroperitoneal lymph-node dissection (L-RPLND) is not only a staging procedure in stage I non-seminomatous germ-cell testicular tumors (NSGCTT): Mature data from a referral centre
13. 20 Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01)
14. 239 Pan-HER trosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemonaive patients (pts)
15. 21 An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumours (GCT): Results at the end of first stage (FM12GCT01)
16. 25 Impact of bleomycin (BLM) administration on the development of pulmonary toxicity in advanced germ cell tumours (GCT) receiving first-line chemotherapy (CT): A meta-analysis of randomized studies
17. 1144 A phase 2 study of the Aurora Kinase-A (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pre-treated urothelial cancer (UC)
18. P025 Predictors of upgrading/upsizing in low-risk prostate cancer patients on active surveillance: Validation of a model
19. P150 Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: A systematic review and meta-analysis of patient outcomes
20. 597 Interim [18F] Fluorodeoxyglucose Positron Emission Tomography (PET) for early metabolic assessment of response to PEB chemotherapy for metastatic seminoma: Preliminary findings
21. 711 Dacomitinib (PF-0299804) in untreated patients (pts) with advanced or metastatic penile squamous cell carcinoma (PSCC): Early findings of an open-label, single-group, phase 2 trial
22. 598 Clinical outcomes of Intermediate Risk metastatic Germ Cell Tumors (IRGCT): Results from a single-institution series
23. 824 PRIAS vs SAINT: Comparing two active surveillance protocols
24. P063 Different predictors of upgrading and upsizing at 1-year repeat biopsy in men with low-risk prostate cancer undergoing active surveillance in prospective trials
25. P065 Active Surveillance in prostate cancer: 8 years' experience
26. P002 Interleukin-8 (IL8) and transforming growth-factor beta (TGF-β) as drugable biomarkers of response, progression-free (PFS) and overall survival (OS) with pazopanib (PZP): A phase 2 study in relapsed urothelial cancer (UC)
27. P068 Active surveillance in prostate cancer: 7 year experience
28. P066 Predictors of upgrading/upsizing after 1-year re-biopsy in men participating in a prospective active surveillance program
29. 1012 PATIENTS CHOOSING ACTIVE SURVEILLANCE: HEALTH- RELATED QUALITY OF LIFE AND ADJUSTMENT TO DISEASE AT THE ENTRANCE IN THE PROTOCOL
30. 1123 Activity of pazopanib in chemoresistant patients with germ cell tumours (GCT): Early findings of the open-label, single-group, phase 2 pazotest-01 trial
31. 784 Quantification and molecular profiling of circulating tumour cells (CTCs) in urothelial cancer (UC) before and during systemic treatment: Implications across the clinical stages
32. 57 Neo-adjuvant and adjuvant combination of a taxane plus cisplatin and 5-fluorouracil in patients undergoing lymph-node dissection for nodal metastases from squamous cell carcinoma (SCC) of the penis: Is there an indication for a recommendable use?
33. 120 The curative potential of lymphadenectomy after response to chemotherapy in patients with urothelial carcinoma presenting with regional or distant nodal metastases: Analysis of a series from a tertiary cancer centre
34. 1119 Total number of positive nodes and positive node ratio may predict recurrence in early stage non-seminomatous germ-cell tumours (NSGCT) undergoing primary retroperitoneal lymph-node dissection (RPLND)
35. 791 Phase 2 study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676)
36. 83 Long-term efficacy and safety outcomes of the modified (simplified) combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) as front-line therapy for unresectable or metastatic urothelial cancer (UC)
37. 388 The characteristics of inguinal lymph nodes may predict pelvic lymph nodes involvement in penile cancer: A single-institutional experience
38. 397 Early results of the pilot study with the anti-Epidermal Growth-Factor Receptor (EGFR) monoclonal antibody Panitumumab in patients (pts) with multi-relapsed or refractory squamous cell carcinoma (SCC) of the penis
39. P085 Risk factors for low quality of life in patients in active surveillance
40. 764 Centralized revision of diagnostic pathologic slides for prostate cancer patients on active surveillance: Is it just time and resource consuming or do we really need it
41. 407 Laparoscopic retroperitoneal lymph node dissection (L-RPLND) in clinical stage I non-seminomatous germ-cell tumours of the testis (NSGCTT): Towards the mini-invasive single strategy option
42. 403 A combination of a taxane plus cisplatin and 5-fluorouracile (T-PF) in advanced penile squamous cell carcinoma (pSCC): Results of a monoinstitutional study
43. 758 Predictors of poor quality of life in patients in active surveillance
44. 561 A COMBINATION OF CISPLATIN AND 5-FLUOROURACIL PLUS A TAXANE FOR ADVANCED SQUAMOUS-CELL CARCINOMA (SCC) OF THE PENIS. A SINGLE INSTITUTION SERIES
45. 726 OPEN (O) AND LAPROSCOPIC (L) RETROPERITONEAL LYMPH-NODE DISSECTION (RPLND) FOR CLINICAL STAGE I NON SEMINOMATOUS GERM-CELL TESTIS TUMOURS (NSGCT): EXPERIENCE OF A SINGLE CENTER
46. 952 TERATOMA WITH MALIGNANT TRANSFORMATION IN ADULT MALE GERM-CELL CANCER: A LARGE RETROSPECTIVE REVIEW AT FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI (INT) OF MILAN
47. 948 OPEN VS. LAPAROSCOPIC RETROPERITONEAL LYMPH-NODE DISSECTION (RPLND) IN CLINICAL STAGE I NON-SEMINOMATOUS GERM-CELL TUMORS (NSGCTS): TWO CONTEMPORARY SERIES FROM A SINGLE INSTITUTION
48. RISK OF DISTANT METASTASIS FOLLOWING RETROPERITONEAL LYMPH-NODE DISSECTION (RPLND) ALONE IN CLINICAL STAGE I (CS I) NON-SEMINOMATOUS GERM CELL TESTICULAR TUMOURS (NSGCTTS)
49. Vascular invasion and percent of embryonal carcinoma in non-seminoma tumours predicts only nodal metastasis in clinical stage 1 patients submitted to retroperitoneal lymph-node dissection (RPLND) alone
50. Is further chemotherapy necessary in radically resected residual cancer in non-seminomatous germ cell tumours (NSGCT) of the testis following induction or salvage chemotherapy?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.